KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Interest & Investment Income (2023 - 2025)

Historic Interest & Investment Income for Neogenomics (NEO) over the last 5 years, with Q3 2025 value amounting to $1.6 million.

  • Neogenomics' Interest & Investment Income fell 6655.25% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 3731.52%. This contributed to the annual value of $18.4 million for FY2024, which is 902.26% up from last year.
  • Latest data reveals that Neogenomics reported Interest & Investment Income of $1.6 million as of Q3 2025, which was down 6655.25% from $2.3 million recorded in Q2 2025.
  • Neogenomics' 5-year Interest & Investment Income high stood at $4.8 million for Q4 2023, and its period low was $1.6 million during Q3 2025.
  • Moreover, its 3-year median value for Interest & Investment Income was $4.4 million (2023), whereas its average is $4.0 million.
  • As far as peak fluctuations go, Neogenomics' Interest & Investment Income surged by 659.24% in 2024, and later plummeted by 6655.25% in 2025.
  • Quarter analysis of 3 years shows Neogenomics' Interest & Investment Income stood at $4.8 million in 2023, then fell by 10.67% to $4.3 million in 2024, then tumbled by 63.89% to $1.6 million in 2025.
  • Its Interest & Investment Income was $1.6 million in Q3 2025, compared to $2.3 million in Q2 2025 and $3.7 million in Q1 2025.